Physitrack (Q1 Initial take): Results close to expectations; RTM and US listing in focus - Redeye

Physitrack’s Q1 2026 report landed close to our overall expectations, maintaining the stable and profitable trajectory the Group has maintained for over a year. While headline revenue growth was modest, the underlying quality of earnings continues to improve through a strategic "SaaS-ification". The imminent launch of Remote Therapeutic Monitoring (RTM) and a potential US listing on OTCQX highlight Physitracks continued expansion into the North American market

Länk till analysen i sin helhet: https://www.redeye.se/research/1160106/physitrack-q1-initial-take-results-close-to-expectations-rtm-and-us-listing-in-focus?utm_source=finwire&utm_medium=RSS